When we last covered Navotek Medical‘s RealEye patient tracking system, it was in its early stages of development. Now, MedCityNews reports that the system has been granted FDA 510(k) approval, clearing the way for Navotek to begin manufacturing and selling the system in the US. The RealEye is designed as an add-on to traditional linear accelerators which are currently used to administer radiation therapy, and allows doctors to track a patient’s movement during treatment in order to minimize damage to the healthy tissues surrounding the cancerous one.
From the product page:
RealEye monitors the target location throughout the treatment, providing a warning in case the target moves beyond a predefined threshold. This may allow stopping the treatment and adjusting the patient position in order to spare the healthy tissue surrounding the target.
Since RealEye is designed to reduce the need for anatomical imaging, its use has the potential to significantly lower the patient’s exposure to non-therapeutic radiation, even taking into account the tracer’s minute radioactive emissions.
MedCityNews coverage: Cleveland-backed Israeli device firm gets FDA clearance…
Product page: RealEye…
Flashback: Radiation Technology from Navotek…